Thrombolytic Therapy Up-regulates Inflammatory Mediators Compared to Percutaneous Coronary Intervention (PCI)
-
Alireza Garjani
,
Bahram Sohrabi
,
Ali Akbar Movassaghpour
,
Sina Andalib
,
Mehriar Shokri
,
Bahar Taherkhanchi
,
Bahador Bagheri
Abstract
The important role of reperfusion therapies in the treatment of acute myocardial infarction is well documented. However, reperfusion therapies can initiate inflammatory response and may damage the myocardium. The purpose of current study was to compare the effects of percutaneous coronary intervention and thrombolytic therapy on inflammatory markers in the setting of ST elevation myocardial infarction (STEMI). Eighty three patients with STEMI were enrolled in this study. 40 patients underwent percutaneous coronary intervention (PCI), and 43 patients received streptokinase (1.5 million IU) as a main medical reperfusion therapy. Monocyte expression of Toll-like receptor 4 (TLR4), serum levels of TNF-α and IL-1β, red cell distribution width (RDW) and C- reactive protein (CRP) were compared between groups at admission time, two hours and four hours after termination of treatment. p<0.05 was considered as statistically significant for all tests. Compared to baseline, both treatments increased monocyte expression of TLR4, serum levels of cytokines and CRP. Compared to PCI, medical reperfusion therapy significantly raised both monocyte expression of TLR4 (39.8±4.7 % vs 49.1±3.6 %, p<0.01), and serum levels of TNF-α (13.2±3.7 pg/ml vs 25.1±2.6pg/mlp<0.05). No effect was seen on RDW levels. Moreover, medical reperfusion therapy caused significant rise in CRP levels (p<0.01). The present study demonstrates that thrombolytic therapy is associated with higher inflammatory responses compared to PCI. Our findings suggest that thrombolytic therapy may increase the likelihood of detrimental effects of reperfusion therapy on the myocardium
1. Finegold JA, Asaria P, Francis DP. Mortality from ischemic heart disease by country, region, and age: Statistics from World Health Organization and United Nations. Int J Cardiol 2012; 168(2):934-45.
2. Ross R. Atherosclerosis-an inflammatory disease. NewEngl J Med 1999; 340(2):115-26.3. Verma S, Paul WM, Fedak W, Butany J, Rao V, Maitland A, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105(20):2332-6.
4. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004; 25(19):1679–87.
5. Takeda K, Akira S. Toll like receptors in innate immunity.Int J Immunol 2005; 17(1):1-14.
6. Takeda K, Akira S. Roles of Toll-like receptors in innateimmune responses. Gen to Cells 2001; 6(9):733-42.
7. Methe H, Kim J, Kofler S, Weis M, Nabauer M, Koglin J.Expansion of circulating Toll-like receptor 4–positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111(20):2654-61.
8. Tsan M, Gao B. Endogenous ligands of Toll-like receptors.J Leuko Bio 2004; 76(3):514-9.
9. Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 2006;86(2):515–81.
10. Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 2008; 117(2):163–8.
11. Baysal E, Çetin M, Yaylak B, Altntaş B, Altndağ R, Adyaman Ş, et al. Roles of the red cell distribution width and neutrophil/lymphocyte ratio in predicting thrombolysis failure in patients with an ST-segment elevation myocardial infarction. Blood Coagul Fibrinolysis 2015; 26(3):274–8.
12. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349(9050):462–6.
13. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312(7038):1061–5.
14. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361(9351):13–20.
15. Bagheri B, Sohrabi B, Movassaghpour A, Mashayekhi S, Garjani A, Shokri M , et al. Monocyte expression of Toll- like receptor-4 in patients with stable angina undergoing percutanoeus coronary intervention. Iran J Immunol 2012; 9(3):149-58.
16. Yellon D, Hausenloy D. Myocardial reperfusion injury. N Engl J Med 2007; 357(11):1121-35.
17. Frangogiannis N. The inflammatory response in myocardial injury, repair, and remodeling. Nat Rev Cardiol 2014; 11(5):255-65.
18. Versteeg D, Hoefer IE, Schoneveld AH, De Kleijin DPV, Busser E, Strijider C, et al. Monocyte Toll-like receptor 2 and 4 response and expression following percutaneous coronary intervention: association between lesion stenosis and fractional flow reserve. Heart 2008; 94(6):770-6.
19. Heine H, Lein E. Toll-like receptors and their functioninnate and adaptive immunity. Int Arch Allergy Immunol2003; 130(3):180-92.20. Vink A, Schoneveld AH, Van der Meer JJ, Van Middelaar BJ, Sluijter JP, Smeets MB, et al. In vivo evidence for a role of Toll-like receptor 4 in the development of intimal lesions. Circulation 2002;106(15):1985-90.
21. Kaisho T, Akira S. Molecular mechanisms in allergy and clinical immunology. J Allergy Clin Immuol 2006;117(5):979-87.
22. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100(8):793-8.
23. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101(18):2149-53.
24. Aggarwal A, Schneider D, Terrien E, Gilbert K, Dauerman H. Increase in interleukin-6 in the first hour after coronary stenting: An early marker of the inflammatory response. J Thromb Thrombolysis 2003;15(1):25-31.
25. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schächinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37(3):839-46.
26. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34(5):1512-21.
27. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J2012; 33(13):1653-701.
28. Lippi G, Targher G, Montagnana M, Salvagno GL,Zoppini G, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med 2009; 133(4):628–32.
29. Lee WS, Kim TY. Relation between red blood cell distribution width and inflammatory biomarkers in rheumatoid arthritis. Arch Pathol Lab Med 2010;134(4):505-6.
30. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, et al. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004;109(6):784-9.
31. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010; 121(1):80-90.
32. Bagheri B, Sohrabi B, Movassaghpour A, Mashayekhi S, Garjani A, Shokri M, et al. Hydrocortisone reduces Toll- like receptor 4 expression on peripheral CD14+ monocytes in patients undergoing percutanoues coronary intervention. Iran Biomed J 2014; 18(2):76-81.
33. Shokri M, Bagheri B, Garjani A, Sohrabi B, Habibzadeh A, Kazemi B, et al. Everolimus eluting stetns reduce monocyte expression of Toll-Like receptor 4. Adv Pharm Bull 2015; 5(Suppl 1):643-7.
34. Grote K, Schütt H, Schieffer B. Toll-like receptors in angiogenesis. TheScientificWorldJOURNAL 2011;11:981-91.
35. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86(2-3):123-30.
36. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108(10):1176-83.
| Files | ||
| Issue | Vol 15, No 4 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Inflammation Percutaneous coronary interventions Reperfusion therapy ST elevation myocardial infarction Toll-like receptor 4 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
